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W
e welcome the increased amount
of solid evidence (1,2) with re-
gard to hyperbaric oxygen treat-
ment(HBOT)asaneffectivetreatmentfor
chronic diabetic foot ulcers in the article
by Lipsky and Berendt (1). One of the
concerns mentioned by Löndahl et al.
(2) is the limited availability and the issue
of cost-effectiveness to convince policy
makers to facilitate hyperbaric oxygen
centers.
HBOT in the Netherlands is widely
available and is relatively inexpensive—
af u l ls e t( 4 0t i m e s / 6 0h )o fH B O Tc o s t s
€6,916.40 (40 3 €172.91) per patient in
each one of the hyperbaric centers in the
Netherlands. This is less expensive than
the $50,000–200,000 mentioned by Lip-
sky and Berendt. All the hyperbaric cen-
ters in the Netherlands only treat indica-
t i o n sa sd e ﬁned by the national health
care reimbursement institute indications.
Consequently charges are only covered
via the institute payment regulations for
these indications. Despite, or perhaps
even because of,theselimitations, allcen-
ters for HBOT in the Netherlands appear
to be cost-effective.
In our 50 years of HBOT experience
(3), HBOT has been shown to beneﬁtp a -
tients with refractory wounds. We com-
pletely agree that HBOT is unnecessary
for the great majority of patients, since
they will respond to appropriate wound
care.However,patientswhoare receiving
HBOTcanlookforwardtohigherquality-
adjusted life-years than found for control
subjects, as mentioned byChuck etal.(4)
Hence, HBOT is cost-effective in the
Netherlands.Clinicalevidenceisgrowing
for effectiveness of HBOT treatment in
patients with chronic diabetic foot ulcers
and should therefore be considered for
patients not responding to standard
wound care.
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